TY - JOUR
T1 - Human peptide transporters
T2 - Therapeutic applications
AU - Nielsen, Carsten Uhd
AU - Brodin, Birger
AU - Jørgensen, Flemming Steen
AU - Frokjaer, Sven
AU - Steffansen, Bente
PY - 2002/9/1
Y1 - 2002/9/1
N2 - Peptide transporters are epithelial solute carriers. Their functional role has been characterised in the small intestine and proximal tubules, where they are involved in absorption of dietary peptides and peptide reabsorption, respectively. Currently, two peptide transporters, PepT1 and PepT2, which possess transport activity, have been identified. The transporters are not drug targets per se, but due to uniquely broad substrate specificity they have proven to be relevant in drug therapy at the level of drug transport. Therapeutic agents such as orally active β-lactam antibiotics, bestatin, prodrugs of acyclovir and gancyclovir have oral bioavailabilities, which are largely a result of their interaction with PepT1. The transporters have therefore received considerable attention in relation to drug delivery. The aim of the present review is to highlight structural requirements for binding to peptide transporters, as well as their role in drug delivery and in potential future drug design and targeted tissue delivery of peptides and peptidomimetics.
AB - Peptide transporters are epithelial solute carriers. Their functional role has been characterised in the small intestine and proximal tubules, where they are involved in absorption of dietary peptides and peptide reabsorption, respectively. Currently, two peptide transporters, PepT1 and PepT2, which possess transport activity, have been identified. The transporters are not drug targets per se, but due to uniquely broad substrate specificity they have proven to be relevant in drug therapy at the level of drug transport. Therapeutic agents such as orally active β-lactam antibiotics, bestatin, prodrugs of acyclovir and gancyclovir have oral bioavailabilities, which are largely a result of their interaction with PepT1. The transporters have therefore received considerable attention in relation to drug delivery. The aim of the present review is to highlight structural requirements for binding to peptide transporters, as well as their role in drug delivery and in potential future drug design and targeted tissue delivery of peptides and peptidomimetics.
KW - β-lactams
KW - Angiotensin converting (ACE) inhibitors
KW - Bestatin
KW - Bisphosphonates
KW - Carrier-mediated drug delivery
KW - Cephalosporins
KW - Di/tripeptide transporter
KW - Drug absorption
KW - hPepT1
KW - hPepT2
KW - Oligopeptide transporter
KW - Renin inhibitors
KW - Thrombin inhibitors
KW - Valacyclovir
KW - Valgancyclovir
U2 - 10.1517/13543776.12.9.1329
DO - 10.1517/13543776.12.9.1329
M3 - Journal article
AN - SCOPUS:0036740580
SN - 1354-3776
VL - 12
SP - 1329
EP - 1350
JO - Expert Opinion on Therapeutic Patents
JF - Expert Opinion on Therapeutic Patents
IS - 9
ER -